Don’t miss your opportunity to be a part of this event, now a highly anticipated Campbell tradition, a decade in the making! More information at: library.campbell.edu/symposium
This medication use evaluation examined areas for improvement in lipid management of 372 patients hospitalized with non-ST elevation ACS and ST elevation ACS at Cape Fear Valley Medical Center from October 2020-2021. The primary outcome assessed percentage of patients appropriately receiving high intensity statin therapy at discharge. Analysis revealed 325 patients (87.3%) were discharged on a high intensity statin, but 123 (37.8%) were eligible for additional therapy with ezetimibe and/or a PCSK9 inhibitor to reach goal LDL. This evaluation highlights a need for greater emphasis on therapeutic optimization, improved provider education, and orderset adjustments to ensure appropriate lipid monitoring post-ACS.
